Zacks: Brokerages Expect OncoSec Medical Inc (ONCS) to Post -$0.20 EPS

Equities analysts expect that OncoSec Medical Inc (NASDAQ:ONCS) will post ($0.20) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for OncoSec Medical’s earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.19). The business is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that OncoSec Medical will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.60). For the next year, analysts forecast that the company will report earnings of ($0.84) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for OncoSec Medical.

A number of analysts have weighed in on the stock. Piper Jaffray Companies restated an “overweight” rating on shares of OncoSec Medical in a research note on Monday, October 15th. HC Wainwright lowered shares of OncoSec Medical from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, Dawson James restated a “buy” rating on shares of OncoSec Medical in a research note on Monday, July 16th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. OncoSec Medical presently has an average rating of “Buy” and an average target price of $4.00.

Several hedge funds have recently made changes to their positions in the company. Nexthera Capital LP grew its stake in shares of OncoSec Medical by 26.6% in the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after acquiring an additional 550,000 shares during the period. Millennium Management LLC grew its stake in shares of OncoSec Medical by 19.5% in the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after acquiring an additional 194,739 shares during the period. 683 Capital Management LLC bought a new stake in shares of OncoSec Medical in the second quarter worth approximately $414,000. BlackRock Inc. grew its stake in shares of OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 221,916 shares during the period. Finally, DRW Securities LLC grew its stake in shares of OncoSec Medical by 157.1% in the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 110,000 shares during the period. Hedge funds and other institutional investors own 23.13% of the company’s stock.

NASDAQ:ONCS traded up $0.02 on Friday, reaching $0.86. 2,243,700 shares of the stock traded hands, compared to its average volume of 1,135,846. The firm has a market cap of $51.72 million, a P/E ratio of -0.81 and a beta of 2.28. OncoSec Medical has a 12 month low of $0.68 and a 12 month high of $2.95.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Featured Article: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply